Stocks · News reference

HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

Sep 30, 2026, 10:18 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 30, 2026, 10:18 AM
Checked: Sep 30, 2026, 10:18 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 29, 2026, 8:10 PMBenzinga Newsdesk
Dyne Therapeutics Continues To Expect Topline Data In Q1 2027 From The Achieve REC, With A Primary Endpoint Of Change From Baseline In vHOT At 6 Months, Intended To Support A Potential Submission For U.S. Accelerated Approval In Q3 2027
DYN
SEC EDGARSep 29, 2026, 8:10 PMSEC EDGAR
8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-09-29 AccNo: 0001818794-26-000009 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
DYN
BenzingaSep 29, 2026, 8:08 PMBenzinga Newsdesk
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
DYN